UY36315A - COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. - Google Patents

COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.

Info

Publication number
UY36315A
UY36315A UY0001036315A UY36315A UY36315A UY 36315 A UY36315 A UY 36315A UY 0001036315 A UY0001036315 A UY 0001036315A UY 36315 A UY36315 A UY 36315A UY 36315 A UY36315 A UY 36315A
Authority
UY
Uruguay
Prior art keywords
avß6
antigonist
integrine
compounds
new
Prior art date
Application number
UY0001036315A
Other languages
English (en)
Inventor
Ashley Paul Hancock
John Martin Pritchard
Joanna Mary Redmond
Matthew Howard James Campbell-Crawford
Niall Andrew Anderson
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY36315A publication Critical patent/UY36315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de fórmula I, en la que R representa H o F, o una sal del mismo.
UY0001036315A 2014-09-26 2015-09-22 COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. UY36315A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417011.2A GB201417011D0 (en) 2014-09-26 2014-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
UY36315A true UY36315A (es) 2016-04-29

Family

ID=51901167

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036315A UY36315A (es) 2014-09-26 2015-09-22 COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.

Country Status (15)

Country Link
US (1) US10000489B2 (es)
EP (1) EP3197893B1 (es)
JP (1) JP6665169B2 (es)
KR (1) KR20170063590A (es)
CN (1) CN107074849A (es)
AR (1) AR101995A1 (es)
AU (1) AU2015320859A1 (es)
BR (1) BR112017006253A2 (es)
CA (1) CA2962326A1 (es)
ES (1) ES2704525T3 (es)
GB (1) GB201417011D0 (es)
RU (1) RU2017114346A (es)
TW (1) TW201629057A (es)
UY (1) UY36315A (es)
WO (1) WO2016046226A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
EP3538527B1 (en) 2016-11-08 2021-10-13 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
KR102515507B1 (ko) 2016-11-08 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 피롤 아미드
TW201819378A (zh) 2016-11-08 2018-06-01 美商必治妥美雅史谷比公司 作為αｖ整合素抑制劑之含環丁烷及氮雜環丁烷之單及螺環化合物
MA46745A (fr) 2016-11-08 2021-03-31 Bristol Myers Squibb Co Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
HUE059708T2 (hu) 2016-11-08 2022-12-28 Bristol Myers Squibb Co 3-szubsztituált propionsavak mint alfa-V-integrin inhibitorok
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
KR20230163575A (ko) 2017-02-28 2023-11-30 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제제
CN107823208A (zh) * 2017-10-25 2018-03-23 南京多宝生物科技有限公司 吗啉类化合物在制备治疗和预防肾纤维化药物中的应用
SG11202004077WA (en) 2017-11-07 2020-05-28 Bristol Myers Squibb Co Pyrrolopyrazine derivatives as alpha v integrin inhibitors
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
UY38352A (es) * 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
US20200071322A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting (alpha-v)(beta-6) integrin
TW202028179A (zh) * 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
WO2020117988A1 (en) * 2018-12-04 2020-06-11 Tolero Pharmaceuticals, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2023225119A1 (en) * 2022-05-18 2023-11-23 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors
WO2024129931A1 (en) 2022-12-14 2024-06-20 Alnylam Pharmaceuticals, Inc. ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100397A3 (en) 1997-12-17 2002-10-28 Merck & Co Inc Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
DZ3263A1 (fr) 1999-06-02 2000-12-07 Merck & Co Inc Antagonistes du recepteur de l'alpha v integrine
WO2000078317A1 (en) 1999-06-23 2000-12-28 Merck & Co., Inc. Integrin receptor antagonists
JP2003510360A (ja) 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
CN1414966A (zh) 1999-11-08 2003-04-30 麦克公司 用于制备咪唑烷酮αu蛋白拮抗剂的方法和中间体
EP1289983A2 (en) 2000-06-15 2003-03-12 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
WO2002007730A1 (en) 2000-07-26 2002-01-31 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
EP1349548A4 (en) 2001-01-03 2004-06-02 Merck & Co Inc METHOD AND COMPOSITIONS FOR TREATING PERIODONTOSIS
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2004058254A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
DK2139882T3 (en) 2007-03-23 2014-03-10 Amgen Inc 3-substituted quinoline or quinoxaline derivatives and their use as inhibitors of phosphatidylinositol 3-kinase (PI3K)
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
RU2017132433A (ru) 2015-02-19 2019-03-19 Сайфлуор Лайф Сайенсиз, Инк. Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
EP3197893A1 (en) 2017-08-02
TW201629057A (zh) 2016-08-16
BR112017006253A2 (pt) 2017-12-12
GB201417011D0 (en) 2014-11-12
JP2017528503A (ja) 2017-09-28
WO2016046226A1 (en) 2016-03-31
CN107074849A (zh) 2017-08-18
AR101995A1 (es) 2017-01-25
US20170298063A1 (en) 2017-10-19
EP3197893B1 (en) 2018-10-24
KR20170063590A (ko) 2017-06-08
JP6665169B2 (ja) 2020-03-13
ES2704525T3 (es) 2019-03-18
US10000489B2 (en) 2018-06-19
AU2015320859A1 (en) 2017-03-09
RU2017114346A (ru) 2018-11-02
CA2962326A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
EA201891211A1 (ru) Ингибиторы cxcr2
UY36314A (es) NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA avß6.
TR201905829T4 (tr) Buzdolabı.
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
DOP2017000178A (es) Inhibidores selectivos de bace1
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
TR201909606T4 (tr) Pi̇razollari hazirlamak i̇çi̇n i̇şlem
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
BR112017005883A2 (pt) compostos herbicidas
AR105967A1 (es) Sales de un inhibidor de pim quinasa
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
BR112016029117A2 (pt) compostos herbicidas
BR112017023150A2 (pt) compostos herbicidas.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
BR112016027455A2 (pt) moduladores ppar
DK3374357T3 (da) Disubstituerede diaryloxybenzoheterodiazol-forbindelser
BR112017002139A2 (pt) ?método para preparar um composto?
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
CL2016003154A1 (es) Composiciones herbicidas sólidas que contienen un fitoprotector
BR112017022809A2 (pt) compostos herbicidas.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705